Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.

Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. J Carcinog. 2019;18:5 Authors: Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S Abstract With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival have been observed among patients with advanced HER2-positive disease. Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA) approval in combination with capecitabine for patients with advanced HER2+ breast cancer. Then, pertuzumab in 2012 and ado-trastuzumab emtansine in 2013 were approved in the US and elsewhere based on evidence showing an improvement in survival outcomes in patients with mostly trastuzumab naïve or trastuzumab-exposed metastatic disease. The FDA also approved 1 year of extended adjuvant neratinib after chemotherapy and a year of trastuzumab for HER2-positive breast cancer on the basis of the ExteNET trial. The clinical benefit demonstrated by those drugs in advanced disease has triggered several adjuvant and neoadjuvant trials testing them in combination with chemotherapy, but also without conventional ...
Source: Journal of Carcinogenesis - Category: Cancer & Oncology Tags: J Carcinog Source Type: research

Related Links:

Conditions:   HER2-positive Breast Cancer;   Chemotherapy Effect;   Circulating Tumor DNA Intervention:   Diagnostic Test: LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark) Sponsor:   Samsung Medical Center Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionesLa colocación de semillas de 125I es una técnica factible para la localización intraoperatoria del ganglio positivo biopsiado en combinación con la BGC. El resultado anatomopatológico del GM permite determinar el estatus axilar posneoadyuvancia.AbstractObjectiveTo present our initial experience in the combined procedure of intraoperative detection of axillary positive node marked with 125I seed (ML) and sentinel node biopsy (SLN) after neoadjuvant chemotherapy (NACT), in breast cancer patients.Material and methodsProspective study, January 2017 – March 2019, 16 breast ca...
Source: Revista Espanola de Medicina Nuclear e Imagen Molecular - Category: Nuclear Medicine Source Type: research
ConclusionAdministration of adjuvant eribulin after neoadjuvant chemotherapy was feasible and well tolerated. The 24-month DFS rate did not reach the study target levels in any of the cohorts and was similar to DFS previously described in these cohorts following neoadjuvant chemotherapy alone.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Abstract PURPOSE: While various studies have highlighted the prognostic significance of pathological complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of additional adjuvant therapy after pCR is not known. EXPERIMENTAL DESIGN: PubMed was searched for studies with NAT for breast cancer and individual patient-level data was extracted for analysis using plot digitizer software. Hazard ratios (HRs), with 95% probability intervals (PIs), measuring the association between pCR and overall survival (OS) or event-free survival (EFS), were estimated using Bayesian piecewise-exponential proportion...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
The positive CTC result is related to patients' age, tumor size, TNM staging, and molecular classification in early breast cancer patients. The total number and CTC ‐positive rate are significantly decreased after NCT in early breast cancer. CTC‐positive converted to negative after chemotherapy presents with a higher pCR rate in patients. AbstractAlthough unequivocal evidence has shown the prognostic relevance of circulating tumor cells (CTCs) in patients with metastatic breast cancer (MBC), less evidence is available for its significance in neoadjuvant chemotherapy (NCT) in early breast cancer (BC). Here we conducted ...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Abstract Objective To identify the biomarkers of response to neoadjuvant chemotherapy in early luminal breast cancer. Methods A cross-sectional study that included all patients with early or locallyadvanced luminal breast cancer submitted to neoadjuvant chemotherapy between 2013 and 2014. Demographic, clinic and pathologic data were retrieved from patient records. The expressions of the estrogen receptor (ER), the progesterone receptor (PR), and Ki67 were analyzed by immunohistochemistry (IHC). The status of the human epidermal growth factor receptor 2 (HER2) was evaluated by IHC and fluorescent in situ hybridization (FISH...
Source: Revista Brasileira de Ginecologia e Obstetricia - Category: OBGYN Source Type: research
CONCLUSION: HER2 FISH ratio showed prognostic value among patients with HER2+ non-IBC but not HER2+ IBC treated with neoadjuvant chemotherapy. This disparity may be due to the underlying aggressive nature of IBC. IMPLICATIONS FOR PRACTICE: The findings of this study indicate that the HER2 to fluorescence in situ hybridization ratio as a continuous variable has promise as a predictor of pathologic complete response to neoadjuvant chemotherapy in patients with HER2-positive (HER2+) noninflammatory breast cancer (non-IBC) regardless of the results on HER2 immunohistochemical testing. In the future, some patients with HER...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
ConclusionsHER2 IHC DIA connectivity is the most important factor predicting pCR to anti-HER2 neoadjuvant chemotherapy in patients with HER2-positive breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Luchinat Corona HER2-positive breast cancer (BC) represents a heterogeneous cancer disease. In an attempt to identify new stratification models useful for prognosis and therapeutic strategy, we investigated the influence of estrogen receptor (ER) status on the host immune and metabolomics profile of HER2-positive BC patients enrolled for neoadjuvant targeted chemotherapy (NATC). The study enrolled 43 HER2-positive BC patients eligible for NATC based on the trastuzumab-paclitaxel combination. Baseline circulatory cytokines and 1H NMR plasma metabolomics profiles were investigated. Differences in the immune cytokines ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Condition:   Invasive Breast Cancer Interventions:   Drug: Cemiplimab;   Drug: Paclitaxel;   Drug: Carboplatin (not mandatory);   Drug: Doxorubicin;   Drug: Cyclophosphamide Sponsor:   Medical College of Wisconsin Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | HER2 | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Xeloda